Mahkam Zanganeh
Principal executive officer pay for Mahkam Zanganeh, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Summit Therapeutics Inc. (SMMT) FY2021–FY2025
Beat peersTSR 550% vs peer group -5% over FY2021–FY2025
Turnaround$100 invested moved from behind the peer group ($57.23 vs $126.42) to ahead ($372.13 vs $119.92) over FY2021–FY2025
Aligned: paid up as stock roseCAP $5,123,646→$233,109,816 while $100 invested went $57.23→$372.13
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $9.6M | $5.1M |
| FY2022 | $1.2M | $3.8M |
| FY2023 | $20.6M | $30.1M |
| FY2024 | $1.2M | $228.3M |
| FY2025 | $246.0M | $233.1M |
The company's "$100 invested" index ran $57.23 at FY2021 → $372.13 by FY2025 — an annualized return of 59.7%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 59.7%/yr at SMMT ( FY2021–FY2025). See the CEO track-record ranking for context.